查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018756

品牌學名藥市場：按劑型、治療領域、應用和分銷管道分類－2026-2032年全球市場預測

Branded Generics Market by Dosage Form, Therapeutic Area, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，品牌學名藥市場價值將達到 5,677.5 億美元，到 2026 年將成長至 6,521.4 億美元，到 2032 年將達到 1.52458 兆美元，複合年成長率為 15.15%。

主要市場統計數據
基準年 2025 5677.5億美元
預計年份：2026年 6521.4億美元
預測年份 2032 15245.8億美元
複合年成長率 (%) 15.15%

受監管監督、供應趨勢以及不斷變化的支付方和處方醫生行為的影響，品牌非專利作為差異化商業資產的策略性採用。

品牌學名藥結合了成熟分子結構的熟悉性與差異化的包裝、配方和行銷策略，從而維繫了醫生和患者的忠誠度，使其在現代醫藥市場中佔據獨特且日益重要的戰略地位。本文旨在闡述品牌學名藥如何不僅作為低成本替代品發揮作用，更作為具有獨特商業性價值的產品，透過信任、供應穩定性和精準分銷，在多元化的醫療保健生態系統中保持價值。

對整個品牌學名藥。

品牌學名藥市場格局正經歷一系列結構性變革，這些變革正在重塑競爭優勢、業務永續營運和商業性可行性。隨著市場監管日益嚴格和統一，品質、序列化和藥品安全監測標準不斷提高，迫使生產商加強品質系統建設並投資於可追溯的供應鏈。同時，數位科技在醫療專業人員和患者中的普及正在改變互動模式，數位管道對處方和購買行為的影響日益增強。

對近期關稅措施如何重塑品牌學名藥相關人員的採購慣例、庫存策略和商業性定位進行全面評估。

美國近期調整關稅和貿易政策措施對品牌學名藥生產商和經銷商的成本結構、籌資策略和商業性策略產生了一系列累積影響。影響原料、中間體和某些包裝組件的關稅提高了依賴全球供應鏈的企業進口投入的相對成本。為此，許多企業正在加快重新評估其供應商組合，並尋找替代來源，以維持獲利能力和供應的連續性。

基於詳細細分的觀點，將劑型、治療領域、適應症和分銷管道聯繫起來，以應對具體的商業性和營運挑戰。

細分市場分析表明，對產品和通路進行精細區分對商業策略和營運重點有顯著影響。在考慮劑型時，必須認知到注射劑可細分為肌肉注射、靜脈注射和皮下注射三種給藥途徑。每種途徑在生產、低溫運輸和給藥方面都有其獨特的考量，這些考量會影響市場進入和價格協商。液體製劑在產品開發和患者依從性方面面臨獨特的挑戰，而懸浮液和糖漿則需要專門的配方知識和包裝技術。片劑和膠囊需要關注速釋和緩釋製劑之間的技術差異，這會影響智慧財產權考量和產品差異化。外用製劑，包括乳膏、凝膠和軟膏，需要進行有針對性的穩定性測試和患者接受度研究，這些都會影響通路選擇和行銷策略的發展。

區域差異化分析表明，監管複雜性、採購行為和製造能力如何獨特地塑造全球市場的品牌非專利策略。

區域趨勢帶來了獨特的機會和挑戰，影響著產品設計、監管策略和供應鏈建構。在美洲，成熟的支付系統和採購機制強調可靠的品質、穩定的供應和具有競爭力的合約。在該地區運營的製造商需要優先考慮符合當地監管機構要求的監管文件，並投資於能夠覆蓋廣泛地域的經銷商夥伴關係。相較之下，歐洲、中東和非洲（EMEA）地區管理體制和採購慣例各異，協調工作與分散的競標流程並存，因此需要適應性強的監管策略和彈性價格設定模式。

這份競爭情報報告概述了生產規模、監管卓越性、數位參與和有針對性的夥伴關係關係如何構成品牌非專利公司的致勝策略。

品牌學名藥領域主要企業之間的競爭格局反映了生產規模、監管合規能力和商業性成熟度的趨同。市場領導透過對品質保證和序列化進行策略性投資來脫穎而出，從而在複雜的競標和報銷環境中確保可靠的供應。一些公司透過深化製劑研發能力，並推出緩釋片、以患者為中心的液體製劑和滿足處方醫生和患者期望的特效外用製劑，延長了產品的生命週期。

透過整合供應鏈韌性、監管合規能力、配方差異化和通路特定商業化來推動競爭優勢的實用建議。

產業領導企業必須採取果斷行動，將當前挑戰轉化為競爭優勢，具體做法是使業務營運投資與商業需求保持一致。首先，他們必須優先考慮供應鏈多元化，並選擇替代的原料藥(API) 和包裝材料供應商，以減少對單一供應區域的依賴。這將確保供應的連續性，並增強其與支付方和經銷商的議價能力。其次，他們必須投資於品管系統、序列化和法規方面的專業知識，以滿足日益嚴格的監管要求，並有助於獲得與醫療機構簽訂的受監管競標和合約。

透明的調查方法，結合第二手資料、專家訪談、案例研究和嚴​​格的檢驗，產生可操作的細分和區域洞察。

本報告的研究基礎在於結合系統的二手資料分析和有針對性的一手檢驗，從而確保其可靠性和可操作性。二級資訊來源包括監管文件、採購框架、公開檢查報告和行業文獻，旨在捕捉結構性趨勢並識別反覆出現的營運挑戰。隨後，研究人員透過與高階主管、採購負責人、監管專家和分銷合作夥伴的深入訪談，對這些洞察進行三角驗證，檢驗檢驗、風險和策略應對措施。

本文簡要概述了嚴格的監管、供應鏈的靈活性和有針對性的商業性執行如何共同決定品牌學名藥行業的成功。

本分析全面檢視了監管變化、貿易政策轉變和不斷演變的商業性動態如何重塑品牌學名藥的市場結構。整體情況，市場格局日益複雜，但同時也為那些能夠將品質系統、供應鏈柔軟性和產品差異化與通路特定商業策略結合的企業帶來了更多機會。那些優先考慮監管準備、投資於以患者為中心的製劑研發並採取區域性策略的企業，將更有利於創造永續價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：品牌學名藥市場：以劑型分類

  • 注射藥物
    • 肌肉內部
    • 靜脈
    • 皮下
  • 液體
    • 懸浮液
    • 糖漿
  • 片劑和膠囊
    • 緩釋
    • 立即生效
  • 外用製劑
    • 奶油
    • 凝膠
    • 軟膏

第9章 品牌學名藥市場：依治療領域分類

  • 感染疾病物
    • 抗生素
    • 抗真菌藥物
    • 抗病毒藥物
  • 循環系統
    • 血脂異常症藥物
    • 抗高血壓藥物
  • 中樞神經系統
    • 抗憂鬱症
    • 抗癲癇藥物
    • 抗精神病藥物
  • 消化器官系統
    • 制酸劑
    • 瀉藥
  • 疼痛管理
    • 非鴉片類鎮痛藥
    • 鴉片類藥物

第10章：品牌學名藥市場：依應用領域分類

  • 動物用藥品
    • 伴侶動物
      • 貓
      • 狗
    • 家畜
  • 人用藥物

第11章 品牌學名藥市場：依通路分類

  • 藥局
  • 醫院藥房
  • 網路藥房
    • 藥房行動應用
    • 網站藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第12章 品牌學名藥市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 品牌學名藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 品牌學名藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國品牌學名藥市場

第16章：中國品牌學名藥市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amneal Pharmaceuticals LLC
  • Apotex Inc.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Endo International PLC
  • Eris Lifesciences Limited
  • Eva Pharma
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Hetero Drugs Limited
  • Lupin Limited
  • Mylan NV by Viatris Inc.
  • Sandoz International GmbH by Novartis Group
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-A26E0E57422E

The Branded Generics Market was valued at USD 567.75 billion in 2025 and is projected to grow to USD 652.14 billion in 2026, with a CAGR of 15.15%, reaching USD 1,524.58 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 567.75 billion
Estimated Year [2026] USD 652.14 billion
Forecast Year [2032] USD 1,524.58 billion
CAGR (%) 15.15%

A strategic introduction that frames branded generics as differentiated commercial assets shaped by regulatory scrutiny, supply dynamics, and evolving payer and prescriber behaviors

Branded generics occupy a unique and increasingly strategic position within contemporary pharmaceutical markets, marrying the familiarity of established molecules with differentiated packaging, formulation, and marketing that sustain physician and patient loyalty. This introduction sets the context for understanding how branded generics function not merely as lower-cost alternatives but as commercially distinct products that leverage trust, supply continuity, and targeted distribution to preserve value across diverse health ecosystems.

Market participants confront converging pressures: evolving payer expectations, heightened scrutiny of quality and traceability, and a greater emphasis on therapeutic differentiation through formulation and adherence features. At the same time, manufacturers are navigating a shifting production landscape where raw material sourcing, regulatory compliance, and manufacturing flexibility determine competitive viability. These dynamics compel a strategic re-evaluation of product portfolios, channel strategies, and partnerships.

Importantly, branded generics are also a vehicle for health access and affordability in many regions. When positioned effectively, they can support adherence and continuity of care by providing recognized alternatives to originator brands while maintaining margins for manufacturers and distributors. This introduction outlines the analytical frame used throughout the report to examine operational, commercial, and regulatory factors, and to surface actionable recommendations for senior leaders seeking to optimize positioning in a crowded and price-sensitive marketplace.

The following sections build on this foundation by tracing the transformative shifts reshaping the landscape, assessing the cumulative impact of trade policy changes, and offering segmentation, regional, and competitive insights that inform pragmatic, revenue-focused decisions.

An in-depth exploration of the structural and operational shifts redefining competitive advantage, quality expectations, and channel engagement across branded generics

The branded generics landscape is being transformed by a set of structural shifts that together recalibrate competitive advantage, operational resilience, and commercial execution. Increased regulatory rigor and harmonization across markets are raising the bar for quality, serialization, and pharmacovigilance, compelling manufacturers to invest in enhanced quality systems and traceable supply chains. Concurrently, digital adoption among healthcare professionals and patients is altering engagement models, with digital channels increasingly influencing prescribing and purchasing behavior.

Supply chain resilience has emerged as a strategic imperative. Companies are balancing cost efficiency with the need for diversified sourcing of active pharmaceutical ingredients, packaging materials, and contract manufacturing capacity. This is accompanied by a revival of regional manufacturing strategies designed to mitigate transport disruptions and tariff exposure. Alongside operational shifts, payers and procurement bodies are refining tender and reimbursement mechanisms to emphasize therapeutic value and continuity of supply, prompting manufacturers to rethink pricing models and contractual commitments.

Another transformative vector is formulation innovation within familiar molecules: extended-release formats, patient-friendly liquid suspensions, and targeted topical forms are being used to differentiate products beyond price. In parallel, the animal health application is gaining prominence, with companion animal therapeutics demanding distinct formulations and marketing approaches compared with livestock care. Collectively, these trends are driving a more sophisticated competitive landscape where manufacturing excellence, regulatory agility, and channel-specific marketing determine long-term success.

The remainder of this analysis tracks how these structural trends interact with trade policy, regional dynamics, and segmentation-specific imperatives to shape opportunities and risks for stakeholders across the value chain.

A cohesive assessment of how recent tariff measures have reshaped sourcing practices, inventory strategies, and commercial positioning for branded generics stakeholders

Recent tariff adjustments and trade policy measures in the United States have created a cumulative set of impacts that ripple across cost structures, sourcing strategies, and commercial tactics for branded generics manufacturers and distributors. Tariffs affecting raw materials, intermediates, and certain packaging components have increased the relative cost of imported inputs for firms that rely on global supply chains. In response, many organizations are reassessing supplier portfolios and accelerating qualification of alternative sources to preserve margin and continuity of supply.

Beyond direct input cost implications, tariff-driven uncertainty has influenced inventory management and contracting behavior. Procurement teams are extending lead times, expanding safety stocks, and renegotiating long-term agreements to lock in favorable terms where possible. Simultaneously, some companies have shifted freight modalities and routing to minimize exposure to tariffed goods, while others have pursued partial onshoring or nearshoring initiatives to localize critical production steps.

On the commercial side, purchasers and payers have become more sensitive to the price impacts that trade measures impart along the supply chain. Manufacturers that can demonstrate localized manufacturing capabilities, verified quality controls, and stable supply histories have gained negotiation leverage in formularies and tender processes. Conversely, firms overly reliant on affected import routes face increased pressure to justify price stability and to present continuity plans.

Taken together, the cumulative effect of tariff changes has catalyzed strategic realignment: supply chain diversification, investment in regional manufacturing footprints, and closer collaboration with distribution partners. These adjustments have significant implications for how branded generics are priced, positioned, and delivered to providers and patients in the evolving policy context.

A granular segmentation-driven perspective that links dosage forms, therapeutic areas, application types, and distribution channels to tailored commercial and operational imperatives

Segmentation analysis reveals that granular product and channel distinctions materially affect commercial strategy and operational priorities. When viewing dosage forms, it is important to recognize that injections are subdivided by intramuscular, intravenous, and subcutaneous routes, each with distinct manufacturing, cold chain, and administration considerations that influence market access and pricing discussions. Liquids present their own set of product development and patient adherence challenges, with suspensions and syrups requiring specialized formulation knowledge and packaging. Tablets and capsules demand attention to immediate release versus extended release technologies, which have implications for intellectual property considerations and differentiation. Topical formulations, encompassing creams, gels, and ointments, require targeted stability testing and patient acceptability studies that shape channel preference and marketing narratives.

Therapeutic area segmentation further refines product strategy. Anti-infectives, including antibiotics, antifungals, and antivirals, remain subject to stewardship policies and regime-specific prescribing dynamics that influence demand patterns. Cardiovascular therapies, split between anti-dyslipidemics and anti-hypertensives, often form the backbone of chronic care portfolios and require reliable adherence support. Central nervous system products, covering anti-depressants, anti-epileptics, and anti-psychotics, necessitate strong safety monitoring and physician engagement to foster trust. Gastrointestinal categories like antacids and laxatives follow distinct seasonality and OTC trade dynamics, while pain management splits between non-opioid analgesics and opioids, the latter demanding stringent regulatory compliance and supply controls.

Application-based segmentation underscores divergent commercialization models for animal health versus human health. Animal health divides into companion animals and livestock, with further focus on cats and dogs within companion segments; these pathways require different regulatory dossiers, distribution partners, and messaging about safety and efficacy. Distribution channel segmentation shapes go-to-market decisions: drug stores, hospital pharmacies, online pharmacies (operating via mobile apps and website platforms), and retail pharmacies (comprised of chain and independent outlets) each present unique trade terms, promotional opportunities, and inventory turnover expectations. A nuanced understanding of these segmentation layers enables companies to prioritize investments, tailor value propositions, and deploy resources where margin and access potential align with operational capabilities.

A regionally differentiated analysis showing how regulatory complexity, procurement behavior, and manufacturing capabilities uniquely shape branded generics strategies across global markets

Regional dynamics create differentiated opportunities and constraints that influence product design, regulatory strategy, and supply chain architecture. In the Americas, established payer systems and mature procurement mechanisms place a premium on demonstrated quality, supply reliability, and competitive contracting; manufacturers operating here must emphasize regulatory dossiers aligned with local authorities and invest in distributor partnerships that support broad geographic reach. Conversely, Europe, Middle East & Africa presents a mosaic of regulatory regimes and procurement practices where harmonization efforts coexist with fragmented tender processes, requiring adaptive regulatory strategies and flexible pricing models.

Asia-Pacific is characterized by rapid demand growth in both human and animal health segments alongside a vibrant manufacturing base. Market participants in this region face intense competition on price but can leverage advanced contract manufacturing and API production capabilities to optimize cost structures. Regional regulatory modernization in parts of Asia-Pacific is increasing alignment with international standards, which improves export potential for compliant manufacturers while raising compliance costs for others. Cross-region trade flows and bilateral trade agreements further interact with local policies to shape where production and distribution investments deliver the best return on effort.

Strategically, organizations must calibrate regional approaches to reflect these differences. Prioritizing investments in quality systems and regional regulatory expertise supports access in regulated markets, while leveraging local manufacturing partnerships and distribution networks can accelerate penetration in growth markets. Ultimately, a regionally differentiated strategy that aligns product design, pricing, and supply chain configuration with local market realities will produce more sustainable outcomes than one-size-fits-all approaches.

A competitive intelligence narrative outlining how manufacturing scale, regulatory excellence, digital engagement, and targeted partnerships define winning strategies among branded generics companies

Competitive dynamics among leading companies in the branded generics sector reflect a blend of manufacturing scale, regulatory acumen, and commercial sophistication. Market leaders are distinguishing themselves through strategic investments in quality assurance and serialization, enabling them to navigate complex tender and reimbursement environments while offering reliable supply. Several firms are deepening capabilities in formulation science to extend product lifecycles by introducing extended-release tablets, patient-centric liquids, and specialty topical forms that meet prescriber and patient expectations beyond price alone.

Consolidation and selective partnerships are also evident, as companies pursue vertical integration or alliances with contract manufacturers to secure API access and scale production in cost-effective jurisdictions. In parallel, a cohort of agile midsize players is focusing on niche therapeutic areas or distribution channels, leveraging speed-to-market and targeted commercial programs to maintain relevance. Digital channel strategies are emerging as a differentiator; incumbents who invest in online pharmacy partnerships, mobile app engagement, and data-driven promotional tactics are seeing better alignment with modern prescribing patterns and patient purchasing behaviors.

Quality and compliance remain central competitive levers. Firms with demonstrated track records in regulatory filings, inspections, and pharmacovigilance are better positioned to win institutional contracts and long-term supply agreements. Strategic acquisition activity, targeted licensing deals, and portfolio rationalization are common tactics for rebalancing pipelines and concentrating resources on higher-value segments where differentiation and margin potential are highest.

Actionable recommendations that align supply chain resilience, regulatory capability, formulation differentiation, and channel-specific commercialization to drive competitive advantage

Industry leaders must act decisively to convert current challenges into competitive advantage by aligning operational investments with commercial imperatives. First, prioritize supply chain diversification and qualification of alternative API and packaging suppliers to reduce dependence on single-source geographies; this supports continuity of supply and strengthens negotiation positions with payers and distributors. Second, invest in quality systems, serialization, and regulatory expertise to meet increasingly stringent oversight and to facilitate access to regulated tenders and institutional contracts.

Third, differentiate through formulation and patient-centric features that enhance adherence and justify premium positioning relative to commodity alternatives; extended-release technologies, palatable liquid formats, and easy-to-apply topicals can create meaningful prescriber preference. Fourth, adopt a channel-specific commercialization playbook that recognizes the distinct economics and engagement tactics required for hospital pharmacies, retail chains, independent outlets, and online pharmacies, and empower local teams to tailor messaging and trade terms accordingly.

Fifth, explore regional manufacturing or contract manufacturing partnerships to mitigate tariff exposure and to improve responsiveness to local demand patterns. Sixth, accelerate digital and data capabilities to inform promotional effectiveness, patient support programs, and direct-to-consumer engagement where regulation permits. Finally, embed scenario planning and regulatory intelligence into strategic planning cycles to detect policy shifts early and to prepare contingency plans that preserve continuity of supply and commercial access.

A transparent methodology that integrates secondary evidence, expert interviews, case studies, and rigorous triangulation to produce actionable segmentation and regional insights

The research underpinning this report combines systematic secondary analysis with targeted primary validation to ensure robustness and practical relevance. Secondary sources included regulatory filings, procurement frameworks, public inspection reports, and industry literature to map structural trends and to identify recurring operational challenges. These insights were then triangulated through in-depth interviews with senior executives, procurement officers, regulatory specialists, and distribution partners to validate drivers, risks, and strategic responses.

Quantitative inputs were contextualized through case studies and company-level profiling to illustrate how different strategic choices translate into operational outcomes. The segmentation framework-spanning dosage forms, therapeutic areas, application types, and distribution channels-was applied consistently to ensure that insights are actionable at both product and channel levels. Regional analyses were informed by country-level regulatory comparisons and visible procurement behaviors to reflect real-world access barriers and opportunities.

Throughout the study, methodological rigor was upheld via cross-validation of primary findings with multiple expert sources and by documenting assumptions and data provenance. Limitations include variability in public data granularity across jurisdictions and the inherent lag between policy announcements and observable market behavior. Nevertheless, the mixed-methods approach provides a defensible evidence base for strategic decisions and for tailoring subsequent bespoke analyses focused on product-specific or geography-specific inquiries.

A concise synthesis of how regulatory rigor, supply chain agility, and targeted commercial execution collectively determine success in the branded generics sector

This analysis synthesizes how regulatory changes, trade policy shifts, and evolving commercial dynamics are reshaping the branded generics landscape. The cumulative picture is one of heightened complexity but also expanded opportunity for organizations that can align quality systems, supply chain flexibility, and product differentiation with channel-specific commercial strategies. Firms that prioritize regulatory readiness, invest in patient-centric formulation, and adopt regionally nuanced approaches will be better placed to capture durable value.

Tariff-driven adjustments have reinforced the need for supply chain agility and strategic localization, while segmentation analysis underscores that success requires product- and channel-specific playbooks rather than uniform approaches. Competitive positioning increasingly hinges on a combination of manufacturing excellence, regulatory performance, and digital engagement, with winners leveraging these capabilities to secure long-term institutional contracts and to maintain prescriber loyalty.

In closing, the branded generics sector offers substantial strategic levers for those willing to invest in capability building and to adapt commercial models to the realities of modern healthcare procurement. The insights herein are intended to guide executive teams as they refine portfolios, prioritize investments, and design resilient operating models that respond to both near-term policy changes and longer-term market evolution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Branded Generics Market, by Dosage Form

  • 8.1. Injections
    • 8.1.1. Intramuscular
    • 8.1.2. Intravenous
    • 8.1.3. Subcutaneous
  • 8.2. Liquids
    • 8.2.1. Suspensions
    • 8.2.2. Syrups
  • 8.3. Tablets & Capsules
    • 8.3.1. Extended Release
    • 8.3.2. Immediate Release
  • 8.4. Topicals
    • 8.4.1. Creams
    • 8.4.2. Gels
    • 8.4.3. Ointments

9. Branded Generics Market, by Therapeutic Area

  • 9.1. Anti-Infectives
    • 9.1.1. Antibiotics
    • 9.1.2. Antifungals
    • 9.1.3. Antivirals
  • 9.2. Cardiovascular
    • 9.2.1. Anti-Dyslipidemics
    • 9.2.2. Anti-Hypertensives
  • 9.3. Central Nervous System
    • 9.3.1. Anti-Depressants
    • 9.3.2. Anti-Epileptics
    • 9.3.3. Anti-Psychotics
  • 9.4. Gastrointestinal
    • 9.4.1. Antacids
    • 9.4.2. Laxatives
  • 9.5. Pain Management
    • 9.5.1. Non-Opioid Analgesics
    • 9.5.2. Opioids

10. Branded Generics Market, by Application

  • 10.1. Animal Health
    • 10.1.1. Companion Animals
      • 10.1.1.1. Cats
      • 10.1.1.2. Dogs
    • 10.1.2. Livestock
  • 10.2. Human Health

11. Branded Generics Market, by Distribution Channel

  • 11.1. Drug Stores
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies
    • 11.3.1. Mobile App Pharmacies
    • 11.3.2. Website Pharmacies
  • 11.4. Retail Pharmacies
    • 11.4.1. Chain Pharmacies
    • 11.4.2. Independent Pharmacies

12. Branded Generics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Branded Generics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Branded Generics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Branded Generics Market

16. China Branded Generics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Amneal Pharmaceuticals LLC
  • 17.6. Apotex Inc.
  • 17.7. Aspen Pharmacare Holdings Limited
  • 17.8. AstraZeneca PLC
  • 17.9. Aurobindo Pharma Limited
  • 17.10. Bausch Health Companies Inc.
  • 17.11. Cipla Limited
  • 17.12. Dr. Reddy's Laboratories Ltd.
  • 17.13. Dr. Reddy's Laboratories Ltd.
  • 17.14. Endo International PLC
  • 17.15. Eris Lifesciences Limited
  • 17.16. Eva Pharma
  • 17.17. Fresenius Kabi AG
  • 17.18. GlaxoSmithKline PLC
  • 17.19. Glenmark Pharmaceuticals Limited
  • 17.20. Hetero Drugs Limited
  • 17.21. Lupin Limited
  • 17.22. Mylan N.V. by Viatris Inc.
  • 17.23. Sandoz International GmbH by Novartis Group
  • 17.24. Sun Pharmaceutical Industries Ltd.
  • 17.25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRANDED GENERICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRANDED GENERICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRANDED GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRANDED GENERICS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRANDED GENERICS MARKET SIZE, BY INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRANDED GENERICS MARKET SIZE, BY INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRANDED GENERICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRANDED GENERICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRANDED GENERICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRANDED GENERICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRANDED GENERICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRANDED GENERICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRANDED GENERICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRANDED GENERICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRANDED GENERICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRANDED GENERICS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRANDED GENERICS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRANDED GENERICS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRANDED GENERICS MARKET SIZE, BY SYRUPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRANDED GENERICS MARKET SIZE, BY SYRUPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRANDED GENERICS MARKET SIZE, BY SYRUPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRANDED GENERICS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRANDED GENERICS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRANDED GENERICS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRANDED GENERICS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRANDED GENERICS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRANDED GENERICS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRANDED GENERICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRANDED GENERICS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRANDED GENERICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRANDED GENERICS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRANDED GENERICS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRANDED GENERICS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRANDED GENERICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRANDED GENERICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRANDED GENERICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DYSLIPIDEMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DYSLIPIDEMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DYSLIPIDEMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-HYPERTENSIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-DEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-EPILEPTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTI-PSYCHOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTACIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANTACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRANDED GENERICS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRANDED GENERICS MARKET SIZE, BY LAXATIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRANDED GENERICS MARKET SIZE, BY LAXATIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRANDED GENERICS MARKET SIZE, BY NON-OPIOID ANALGESICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRANDED GENERICS MARKET SIZE, BY NON-OPIOID ANALGESICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRANDED GENERICS MARKET SIZE, BY NON-OPIOID ANALGESICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRANDED GENERICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRANDED GENERICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRANDED GENERICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRANDED GENERICS MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRANDED GENERICS MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRANDED GENERICS MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRANDED GENERICS MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRANDED GENERICS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BRANDED GENERICS MARKET SIZE, BY HUMAN HEALTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRANDED GENERICS MARKET SIZE, BY HUMAN HEALTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BRANDED GENERICS MARKET SIZE, BY HUMAN HEALTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BRANDED GENERICS MARKET SIZE, BY DRUG STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRANDED GENERICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BRANDED GENERICS MARKET SIZE, BY MOBILE APP PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRANDED GENERICS MARKET SIZE, BY MOBILE APP PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BRANDED GENERICS MARKET SIZE, BY MOBILE APP PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRANDED GENERICS MARKET SIZE, BY WEBSITE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BRANDED GENERICS MARKET SIZE, BY WEBSITE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRANDED GENERICS MARKET SIZE, BY WEBSITE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BRANDED GENERICS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRANDED GENERICS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BRANDED GENERICS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRANDED GENERICS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BRANDED GENERICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS BRANDED GENERICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 299. GLOBAL BRANDED GENERICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 300. ASEAN BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 301. ASEAN BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 302. ASEAN BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 303. ASEAN BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 304. ASEAN BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 305. ASEAN BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 306. ASEAN BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 307. ASEAN BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 308. ASEAN BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 309. ASEAN BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 310. ASEAN BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 311. ASEAN BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 312. ASEAN BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 313. ASEAN BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 314. ASEAN BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 315. ASEAN BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 316. ASEAN BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 317. ASEAN BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 318. GCC BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 319. GCC BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 320. GCC BRANDED GENERICS MARKET SIZE, BY INJECTIONS, 2018-2032 (USD MILLION)
  • TABLE 321. GCC BRANDED GENERICS MARKET SIZE, BY LIQUIDS, 2018-2032 (USD MILLION)
  • TABLE 322. GCC BRANDED GENERICS MARKET SIZE, BY TABLETS & CAPSULES, 2018-2032 (USD MILLION)
  • TABLE 323. GCC BRANDED GENERICS MARKET SIZE, BY TOPICALS, 2018-2032 (USD MILLION)
  • TABLE 324. GCC BRANDED GENERICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 325. GCC BRANDED GENERICS MARKET SIZE, BY ANTI-INFECTIVES, 2018-2032 (USD MILLION)
  • TABLE 326. GCC BRANDED GENERICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 327. GCC BRANDED GENERICS MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 328. GCC BRANDED GENERICS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 329. GCC BRANDED GENERICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 330. GCC BRANDED GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 331. GCC BRANDED GENERICS MARKET SIZE, BY ANIMAL HEALTH, 2018-2032 (USD MILLION)
  • TABLE 332. GCC BRANDED GENERICS MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 333. GCC BRANDED GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 334. GCC BRANDED GENERICS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 335. GCC BRANDED GENERICS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 336. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION BRANDED GENERICS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 338. EUROPEAN UNION BRAND